Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-6345 Phase 1 in Healthy Subjects
NCT03809039Phase 1Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-6345 (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Adverse Events at 6 weeks. Started Jan 2019; status: terminated.
02
Drugs
MT-6345
Beyond the preview
Go deeper on NCT03809039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809039.